



AMGEN TO PRESENT LONG-TERM OUTCOMES FOR LUMAKRAS® (SOTORASIB) IN KRAS G12C-MUTATED NSCLC AT AACR 2022

March 8, 2022

Late-Breaking Oral Presentation Includes Two-Year Follow-Up Data from CodeBreaK 100 Study - the Most Advanced KRAS G12C Clinical Dataset

Pre-Clinical Data Evaluating Half-Life Extended BiTE® Molecule AMG 794 Targeting CLDN6 to be Presented for the First Time

THOUSAND OAKS, Calif., March 8, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that new data from across its oncology portfolio and pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting from April 8-13 in New Orleans, Louisiana.

Long-term outcomes from the CodeBreaK 100 trial of LUMAKRAS® (sotorasib), the first and only KRAS^{G12C} inhibitor approved for patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), will be shared as a late-breaking oral presentation on Sunday, April 10, 2022 from 3:00 – 5:00 p.m. CST.

Notable data from Amgen's oncology pipeline includes the first disclosure of preclinical results from AMG 794, a half-life extended (HLE) bispecific T-cell engager (BiTE®) molecule targeting Claudin 6 (CLDN6) in NSCLC and epithelial ovarian cancer, and TNB-928b, a T-cell engaging bispecific antibody utilizing a bivalent tumor-selective folate receptor alpha binding arm for the treatment of ovarian cancer.

"Following the approval of LUMAKRAS for KRAS G12C-mutated non-small cell lung cancer in nearly 40 countries around the world, we look forward to sharing the longest follow-up data ever presented with a KRAS^{G12C} inhibitor at this year's AACR conference, further demonstrating the clinical benefit this transformative therapy can bring to patients," said David M. Reese, M.D., executive vice president of Research and Development at Amgen. "Across our oncology pipeline, we also look forward to sharing emerging early research highlighting how Amgen is advancing the next frontier of innovation in the treatment of cancers."

With the exception of late-breaking research, abstracts are available and can be viewed on the AACR website.

Abstracts and Presentation Times:

Amgen Sponsored Abstracts

LUMAKRAS

- **Long-term outcomes with sotorasib in pretreated KRAS p.G12C mutated NSCLC: 2-year analysis of CodeBreaK100**
Abstract #7597, Late-Breaking Oral Presentation, Session: Clinical Trials Targeting the DNA Damage Response and KRAS, Sunday, April 10 from 3:00 – 5:00 p.m. CST
- **LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAks and sensitizes KRAS-mutant non-small cell lung cancers to combined KRAS G12C + MCL-1 blockade**
Abstract #2150, Oral Presentation, Mini-Symposium, Session: Monday, April 11 from 2:30 – 4.30 p.m. CST

BiTE® Platform

- **AMG 794, a Claudin 6-targeted half-life extended bispecific T-cell engager (HLE BiTE®) molecule for non-small cell lung cancer and epithelial ovarian cancer**
Abstract #5202, E-Poster Virtual Presentation, Session: Clinical Research Excluding Trials – Immuno-Oncology, Friday, April 8 – Wednesday, April 13
- **Evaluation of a Dual CD123-FLT3 BiTE® Molecule Targeting Acute Myeloid Leukemia**
Abstract #2900, E-Poster In-Person Presentation, Session: Therapeutic Antibodies 2, Tuesday, April 12 from 9:00-12.30 p.m. CST
- **Evaluation of a dual-targeting BCMA-CS1 HLE BiTE® molecule for multiple myeloma**
Abstract #2031, E-Poster Virtual Presentation, Session: Therapeutic Antibodies 1, Friday, April 8 – Wednesday, April 13

MTA-Cooperative PRMT5 Inhibitor

- **The Discovery and Preclinical Characterization of the MTA Cooperative PRMT5 Inhibitor AM-9747**
Abstract #2114, E-Poster In-Person Presentation, Session: Drug Targets, April 11 from 1:30-5:00 p.m. CST

Partner-Led Abstracts

- **Delta-like ligand 3 immunohistochemical expression landscape in high-grade lung neuroendocrine tumors**
Abstract #3690, E-Poster Virtual Presentation, Session: Drug Discovery, Friday, April 8 – Wednesday, April 13
- **A T-cell engaging bispecific antibody utilizing a bivalent tumor-selective folate receptor alpha binding arm for the**

treatment of ovarian cancer

Abstract #2904, E-Poster In-Person Presentation, Session: Therapeutic Antibodies 2, Tuesday, April 12 from 9:00-12:30 p.m. CST

About LUMAKRAS®/LUMYKRAS® (sotorasib)

Amgen took on one of the toughest challenges of the last 40 years in cancer research by developing LUMAKRAS/LUMYKRAS, a KRAS^{G12C} inhibitor.¹ LUMAKRAS/LUMYKRAS has demonstrated a positive benefit-risk profile with rapid, deep, and durable anticancer activity in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation with a once daily oral formulation.²

Amgen is progressing the largest and broadest global KRAS^{G12C} inhibitor development program with unparalleled speed and exploring more than 10 sotorasib combination regimens, including triplets, with clinical trial sites spanning five continents. To date, over 4,000 patients around the world have received LUMAKRAS/LUMYKRAS through the clinical development program and commercial use.

In May 2021, LUMAKRAS was the first KRAS^{G12C} inhibitor to receive regulatory approval anywhere in the world with its approval in the U.S., under accelerated approval. LUMAKRAS/LUMYKRAS is also approved in the United Arab Emirates, the European Union Switzerland, and Japan, and in Canada and Great Britain under the FDA's Project Orbis. Through Project Orbis, Amgen also has Marketing Authorization Applications (MAAs) for sotorasib in review in Australia, Brazil, Singapore, and Israel. Additionally, Amgen has submitted MAAs in Turkey, Taiwan, Colombia, Thailand, Mexico, Hong Kong, Saudi Arabia, Argentina, Kuwait and Qatar.

LUMAKRAS/LUMYKRAS is also being studied in multiple other solid tumors.³

About Non-Small Cell Lung Cancer and the KRAS G12C Mutation

Lung cancer is the leading cause of cancer-related deaths worldwide, and it accounts for more deaths worldwide than colon cancer, breast cancer and prostate cancer combined.⁴ Overall survival rates for NSCLC are improving but remain poor for patients with advanced disease and 5-year survival is only 7% for those with metastatic disease.⁵

KRAS G12C is the most common KRAS mutation in NSCLC.⁶ About 13% of patients with NSCLC harbor the KRAS G12C mutation.⁷ Unmet medical need remains high and treatment options are limited for NSCLC patients with the KRAS G12C mutation whose first-line treatment has failed to work or has stopped working. The outcomes with other approved therapies are suboptimal, with a median progression-free survival of approximately 4 months following second-line treatment of KRAS G12C-mutated NSCLC.⁸

About CodeBreak

The CodeBreak clinical development program for Amgen's drug sotorasib is designed to study patients with an advanced solid tumor with the KRAS G12C mutation and address the longstanding unmet medical need for these cancers.

CodeBreak 100, the Phase 1 and 2, first-in-human, open-label multicenter study, enrolled patients with KRAS G12C-mutant solid tumors.⁹ Eligible patients must have received a prior line of systemic anticancer therapy, consistent with their tumor type and stage of disease. The primary endpoint for the Phase 2 study was centrally assessed objective response rate. The Phase 2 trial in NSCLC enrolled 126 patients, 124 of whom had centrally evaluable lesions by RECIST at baseline.² The Phase 2 trial in colorectal cancer (CRC) is fully enrolled and results have been published.¹⁰

CodeBreak 200, the global Phase 3 randomized active-controlled study comparing sotorasib to docetaxel in KRAS G12C-mutated NSCLC completed enrollment of 345 patients. Eligible patients had previously treated, locally advanced and unresectable or metastatic KRAS G12C-mutated NSCLC. The primary endpoint is progression-free survival and key secondary endpoints include overall survival, objective response rate, and patient-reported outcomes.¹¹

Amgen also has several Phase 1b studies investigating sotorasib monotherapy and sotorasib combination therapy across various advanced solid tumors (CodeBreak 101) open for enrollment.¹² A Phase 2 randomized study will evaluate sotorasib in patients with stage IV KRAS G12C-mutated NSCLC in need of first-line treatment (CodeBreak 201).¹³

For information, please visit www.hcp.codebreaktrials.com.

LUMAKRAS® (sotorasib) U.S. Indication

LUMAKRAS is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

LUMAKRAS® (sotorasib) Important U.S. Safety Information

Hepatotoxicity

- LUMAKRAS can cause hepatotoxicity, which may lead to drug-induced liver injury and hepatitis.
- Among 357 patients who received LUMAKRAS in CodeBreak 100, hepatotoxicity occurred in 1.7% (all grades) and 1.4% (Grade 3). A total of 18% of patients who received LUMAKRAS had increased alanine aminotransferase (ALT)/increased aspartate aminotransferase (AST); 6% were Grade 3 and 0.6% were Grade 4. In addition to dose interruption or reduction, 5% of patients received corticosteroids for the treatment of hepatotoxicity.
- Monitor liver function tests (ALT, AST and total bilirubin) prior to the start of LUMAKRAS every 3 weeks for the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop

transaminase and/or bilirubin elevations.

- Withhold, dose reduce or permanently discontinue LUMAKRAS based on severity of adverse reaction.

Interstitial Lung Disease (ILD)/Pneumonitis

- LUMAKRAS can cause ILD/pneumonitis that can be fatal. Among 357 patients who received LUMAKRAS in CodeBreak 100, ILD/pneumonitis occurred in 0.8% of patients, all cases were Grade 3 or 4 at onset, and 1 case was fatal. LUMAKRAS was discontinued due to ILD/pneumonitis in 0.6% of patients.
- Monitor patients for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Immediately withhold LUMAKRAS in patients with suspected ILD/pneumonitis and permanently discontinue LUMAKRAS if no other potential causes of ILD/pneumonitis are identified.

Most Common Adverse Reactions

- The most common adverse reactions \geq 20% were diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity and cough.

Drug Interactions

- Advise patients to inform their healthcare provider of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, dietary and herbal products.
- Inform patients to avoid proton pump inhibitors and H₂ receptor antagonists while taking LUMAKRAS.
- If coadministration with an acid-reducing agent cannot be avoided, inform patients to take LUMAKRAS 4 hours before or 10 hours after a locally acting antacid.

Please see LUMAKRAS full [Prescribing Information](#).

About BiTE[®] Technology

BiTE[®] (bispecific T-cell engager) technology is a targeted immuno-oncology platform that is designed to engage patient's own T-cells to any tumor-specific antigen, activating the cytotoxic potential of T-cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different tumor types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. Amgen is advancing a number of BiTE molecules across a broad range of hematologic malignancies and solid tumors, further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential.

To learn more about BiTE[®] technology, visit www.AmgenBiTETechnology.com.

About Amgen Oncology

At Amgen Oncology, our mission to serve patients drives all that we do. That's why we're relentlessly focused on accelerating the delivery of medicines that have the potential to empower all angles of care and transform the lives of people with cancer.

For the last four decades, we have been dedicated to discovering the firsts that matter in oncology and to finding ways to reduce the burden of cancer. Building on our heritage, Amgen continues to advance the largest pipeline in the Company's history, moving with great speed to advance those innovations for the patients who need them.

At Amgen, we're advancing oncology at the speed of life™.

For more information, follow us on www.twitter.com/amgenoncology.

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2021, Amgen was named one of the 25 World's Best Workplaces™ by Fortune and Great Place to Work™ and one of the 100 most sustainable companies in the world by *Barron's*.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Forward-Looking Statements

This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd., Kyowa-Kirin Co., Ltd., Generate Biomedicines, Inc., Arrakis Therapeutics, Inc., Plexium, Inc., or any collaboration to manufacture therapeutic antibodies against COVID-19), the performance of Otezla[®] (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), the Five Prime Therapeutics, Inc. acquisition, or the Teneobio, Inc. acquisition, as well as estimates of revenues, operating margins, capital expenditures, cash, other

financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.

Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Further, any scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses.

CONTACT: Amgen, Thousand Oaks
Megan Fox, 805-447-1423 (media)
Michael Strapazon, 805-313-5553 (media)
Arvind Sood, 805-447-1060 (investors)

‡LUMAKRAS, LUMYKRAS, and Advancing Oncology at The Speed of Life are trademarks of Amgen Inc.

¹Canon J, et al. *Nature*. 2019;575: 217–223.

² Skoulidis F, et al. *N Engl J Med*. 2021;384:2371-2381.

³Hong DS, et al. *N Engl J Med*. 2020;383:1207-1217.

⁴ Sung H, et al. *CA Cancer J Clin*. 2021; 71:209-249.

⁵ American Cancer Society. Lung Cancer Survival Rates. 2021. Available at: <https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html>. Accessed on February 22, 2022.

⁶ Arbour KC, et al. *Clin Cancer Res*. 2018; 24:334-340.

⁷ Nassar AF, et al. *N Engl J. Med*. 2021;384:185-187.

⁸ Spira AI, et al. *Lung Cancer*. 2021;159 :1-9

⁹ ClinicalTrials.gov. CodeBreak 100. Available at: <https://clinicaltrials.gov/ct2/show/NCT03600883?term=codebreak&draw=2&rank=4>. Accessed on February 22, 2022.

¹⁰ Fakih MG, et al. *Lancet Oncol*. 2022;23:115-124.

¹¹ [Clinicaltrials.gov](https://clinicaltrials.gov). Codebreak 200. Available at: <https://clinicaltrials.gov/ct2/show/NCT04303780?term=codebreak+200&draw=2&rank=1>. Accessed on February 22, 2022.

¹² [Clinicaltrials.gov](https://clinicaltrials.gov). CodeBreak 101. Available at: <https://clinicaltrials.gov/ct2/show/NCT04185883?term=codebreak&draw=2&rank=3>. Accessed on February 22, 2022.

¹³ [Clinicaltrials.gov](https://clinicaltrials.gov). CodeBreak 201. Available at: <https://clinicaltrials.gov/ct2/show/NCT04933695?term=codebreak+201&draw=2&rank=1>. Accessed on February 22, 2022.



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/amgen-to-present-long-term-outcomes-for-lumakras-sotorasib-in-kras-g12c-mutated-nscl-at-aacr-2022-301498180.html>

SOURCE Amgen